SEARCH

SEARCH BY CITATION

Reference

  • 1
    Schenk R, Merz WA, Mühlbauer R, Russell RGG, Fleisch H: Effect of ethane-l-hydroxy-l, l-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calc Tiss Res 11: 196214, 1973
  • 2
    Bijvoet OLM, Jansen AP: Thyrocalcitonin in Paget's disease. Lancet ii: 471472, 1976
  • 3
    Woodhouse NJY, Reiner M, Bordier P, Kalu DN, Fisher MT, Foster GV, Joplin GF, MacIntyre I: Human calcitonin in the treatment o Paget's bone disease. Lancet 1: 11391143, 1971
  • 4
    Evans IMA, Banks L, Doyle FH, Joplin GF, Pennock J, Stevenson JC, MacIntyre I: Paget's disease of bone: the effect of stopping long term human calcitonin and recommendations for future treatment. Metab Bone Dis Rel Res 2: 8791, 1980
  • 5
    Khairi MRA, Altman RD, de Rosa GP, Zimmermann J, Schenk RK, Johnston CC: Sodium etidronate in the treatment of Paget's disease of bone: a study of long term results. Ann Intern Med 87: 656663, 1977
  • 6
    Frijlink WB, Bijvoet OLM, Te Velde J, Heynen G: Treatment of Paget's disease with (3-amino-l-hydroxypropylidene)-l, l-bisphosphonate (APD). Lancet i: 799803, 1979
  • 7
    Smith R, Russell RGG, Bishop M: Diphosphonates and Paget's disease of bone. Lancet i: 945947, 1971
  • 8
    Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN, Sankey RR: Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 289: 13791384, 1973
  • 9
    Hosking DJ, Bijvoet OLM, Van Aken J, Will EJ: Paget's bone disease treated with diphosphonate and calcitonin. Lancet i: 615617, 1975
  • 10
    Meunier PJ, Chapuy MC, Alexandre C, Bressot C, Edouard C, Vignon E. Mathieu L. Trechsel U: Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet ii: 489492, 1979
  • 11
    Bijvoet OLM, Hosking DJ, Lemkes HHPJ, Reitsma PH, Frijlink W: Development in the treatment of Paget's disease, Endocrinology of Calcium Metabolism. Edited by RVTalmage. Amsterdam, Excerpta Medica, 1977, pp 4854
  • 12
    Russell RGG, Fleisch H: Pyrophosphate and diphosphonales, The Biochemistry and Physiology of Bone. Vol IV. Edited by GHBourne. New York, Academic Press, 1976, pp 61104
  • 13
    Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, Van der Wee-Pals: Kinetic studies of bone and mineral metabolism during treatment with (3-amino-l-hydroxypropylidene)-l, l-bisphosphonate (APD) in rats. Calcif Tiss Intern in press, 1980
  • 14
    Russell RGG, Kislig AM, Casey PA, Fleisch H, Thornton J, Schenk R, Williams DA: Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone. Calc Tiss Res 11: 179195, 1973
  • 15
    Gasser AB, Morgan DB, Fleisch HA, Richelle LJ: The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43: 3145, 1972
  • 16
    Miller Sc, Jee WSS: The comparative effects of dichloromethylene diphosphonate (Cl2MDP) and ethane-l-hydroxy-l,l-diphosphonate (EHDP) on growth and modelling of the rat tibia. Calc Tiss Res 23: 207214, 1977
  • 17
    Bijvoet OLM, Hosking DJ, Frijlink WB, Te Velde J, Vellenga CJLR: Treatment of Paget's disease with combined calcitonin and diphosphonate (EHDP). Metab Bone Dis Rel Res 1: 251261, 1978
  • 18
    Reitsma PH, Bijvoet OLM, Frijlink WB, Vismans FJFE, van Breukelen FJM: Pharmacology of disodium (3-amino-l-hydroxypropylidene)-l, l-bisphosphonate, Proceedings of the Fourth International Workshop on Phosphate and Other Minerals. Edited by SGMassry. New York, Plenum Press, 1980
  • 19
    Loutit JF, Nisbet NW: Resorption of bone. Lancet ii: 2628, 1979
  • 20
    Coccia AF, Krivit W, Cervenka J, Clawson C, Kersey JH, Kim TH, Nesbit ME, Ramsay NKC, Warkentin PJ, Teitelbaum SL, Kahn RJ, Brown DM: Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 302: 701708, 1980
  • 21
    Miller SC, Jee WSS, Kimmel DB, Woodbury L: Ethane-l-hydroxy-l, l-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calc Tiss Res 22: 243245, 1977
  • 22
    Evans RA, Baylink DJ, Wergedal J: The effects of two diphosphonates on bone metabolism in the rat. Metab Bone Dis Rel Res 2: 3948, 1979
  • 23
    Marks SC: Pathogenesis of osteopetrosis in the ia rat: reduced resorption due to reduced osteoclast function. Am J Anat 138: 165190, 1973
  • 24
    Vismans FJFE, Frijlink WB, te Velde J, Bijvoet OLM: Unpublished observations
  • 25
    Mundy GR, Varani J, Orr W, Gondek MD, Ward PA: Resorbing bone is chemotactic for monocytes. Nature 275: 132135, 1978
  • 26
    Olsen ChE, Wahl S, Wahl LM, Sandberg AL, Mergenhagen SE: Immunological defects in osteopetrotic mice, Mechanisms of Localized Bone Loss. Edited by JEHorton, TMTarpley, WFDavis. Washington DC, Information Retrieval Inc, 1977, pp 389398
  • 27
    Walker DG: Spleen cells transmit osteopetrosis in mice. Science 190: 785787, 1975
  • 28
    Yoneda T, Mundy GR: Monocytes regulate osteoclast-activating factor production by releasing prostaglandins. J Exp Med 150: 338350, 1979
  • 29
    Walker DG: Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 190: 784785, 1975
  • 30
    Allison AC: Macrophage activation and nonspecific immunity. Int Rev Exp Pathol 18: 303346, 1978
  • 31
    Francis MB, Flora L, King WR: The effects of disodium ethane-l-hydroxy-l, l-diphosphonate in adjuvant induced arthritis in rats. Calc Tiss Res 9: 109121, 1972
  • 32
    Flora L: Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 22: 340346, 1979
  • 33
    Smith R, Russell RGG, Bishop M: Paget's disease of bone: experience with a diphosphonate (disodium etidronate) in treatment. Q J Med New Series 42: 235256, 1974
  • 34
    Kantrowitz FG, Byrne MH, Schiller AL, Krane SM: Clinical and biochemical effects of diphosphonate in Paget's disease of bone. Arthritis Rheum 18: 407, 1975
  • 35
    Finerman GAM, Gonick HC, Smith RK, Mayfield JM: Diphosphonate treatment of Paget's disease. J Clin Orthop Rel Res 120: 115124, 1976
  • 36
    Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP: Calcitonin or diphosphonates for osteolytic Paget's disease? Lancet i: 374, 1980
  • 37
    Canfield R, Rosner W, Skinner J, McWhorter J, Resnick L, Feldman F, Kammermans S, Ryan K, Kunigonis M, Bohne W: Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 44: 96106, 1977
  • 38
    Reitsma PH, Bijvoet OLM: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma, correspondence. N Engl J Med 303: 162163, 1980
  • 39
    Heynen G: In preparation
  • 40
    Beisel WR, Pekarek RS, Wannemacher RW: Homeostatic mechanisms affecting plasma zinc levels in acute stress, Trace Elements in Human Health and Disease. Vol 1. Edited by ASPrasad, DOberleas. New York, Academic Press, 1976, pp 87106
  • 41
    McConnell I: Structure and function of lymphoid tissue, The Immune System. Edited by MJHobarth, IMcConnel. Oxford, Blackwell 1978, pp 206223
  • 42
    Bernier GM, Fanger MW: Synthesis of β2-microglobulin by stimulated lymphocytes. J Immunol 109: 407409, 1972
  • 43
    Bonta IL, Parnham MJ: Prostaglandins and chronic inflammation. Biochem Pharmacol 27: 16111623, 1978
  • 44
    Parnham MJ, Bonta IL, Adolfs MJP: Interactions between prostaglandin E and cyclic nucleotides in chronic inflammatory disease, Perspectives in Inflammation. Edited by DAWilloughby, JPGirond, GPVelo. Lancaster, MTP Press, 1977, pp 279287
  • 45
    Rebel A, Malkani A, Basle M, Bregeon C: Osteoclast ultrastructure in Paget's disease. Calcif Tiss Res 20: 187199, 1976
  • 46
    Singer F, Mills BG, Terry R: Bone resorbing cells in Paget's disease, Mechanisms of Localized Bone Loss. Edited by JEHorton, TMTarpley, WFDavis. Washington DC, Information Retrieval Inc, 1977, pp 365374
  • 47
    Haslhofer L: Die Pagetschen Knockenkrankheit, Handbuch der speziellen pathologischen Anatomie und Histologie. Edited by OLubarsch, FHenke. Berlin, Julius Springer Verlag, 1937, pp 551616
  • 48
    de Vries JE, Caviles AP, Bont WS, Mendelsohn J: The role of monocytes in human lymphocyte activation by mitogens. J Immunol 122: 10991107, 1979
  • 49
    Rinehart JJ, Orser M, Kaplan ME: Human monocyte and macrophage modulation of lymphocyte proliferation. Cell Immunol 44: 131143, 1979
  • 50
    de Vries E, Lafeber GJM, van der Wey JP, Buysen AC, Leijk PCJ, Cats A: Pokeweed mitogen induced lymphocyte proliferation: the effect of stimulation on mononuclear cells. J Immunol, in press, 1980
  • 51
    de Vries E, van de Putte EBL, Lafeber GJM, van Buysen-Nutters AC, de Vetten-van der Hulst HLM: Morphological differences in the interactions between human mononuclear cells and coated or uncoated sheep red blood cells: a freeze-etch study of different types of rosettes. Cell Tiss Res 168: 7988, 1976
  • 52
    van Breukelen FJM, Bijvoet OLM, van Oosterom AT: Inhibition of osteolytic bone lesions by (3-amino-l-hydroxypropylidene)-l,l-bisphosphonate (APD). Lancet i: 803805, 1979
  • 53
    Minne H, Klü H, Ziegler R, Bijvoet OLM: Treatment of paraneoplastic hypercalcemia in Walker tumor bearing rats with the diphosphonate APD. Mineral Electrolyte Metab 2: 251252, 1979